Literature DB >> 25764625

Orthotopic liver transplantation at King Chulalongkorn Memorial Hospital: a report.

Bunthoon Nonthasoot, Boonchoo Sirichindakul, Jade Suphapol, Wipusit Taesombat, Methee Sutherasan, Supanit Nivatvongs.   

Abstract

Orthotopic liver transplantation (LT) is the treatment of choice for various liver diseases including early hepatocellular carcinoma (HCC). After the first successful LT in Thailand at King Chulalongkorn Memorial Hospital (KCMH) in 1987, the number of LT has gradually been increasing in parallel with the improvement in patient survival. The recent outcomes of LT are reported herein. From January 1, 2002 to June 30, 2013, 120 cases of adult LT and 24 cases of pediatric LT were performed. The most common indication for LT was HCC in the adult whereas biliary atresia was the most common indication for LT in pediatric patients. As for the severity of liver disease, the average model of end stage liver disease (MELD) and pediatric end stage liver disease (PELD) scores were 19 in adult LT and 21.5 in pediatric LT respectively. The most common perioperative complication in adult LT was acute renal failure (25%). One-, five-year patient survival in adult LT and pediatric LT were 85%, 69% and 96%, 91%, respectively. In conclusion, the outcomes of LT at KCMH have gradually been improving close to the world standard, especially the patient survival.

Entities:  

Mesh:

Year:  2015        PMID: 25764625

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  2 in total

1.  Pediatric liver transplantation outcomes from a single center in Thailand.

Authors:  Sittichoke Prachuapthunyachart; Palittiya Sintusek; Chomchanat Tubjareon; Nataruks Chaijitraruch; Anapat Sanpavat; Teerasak Phewplung; Piyaporn Wanawongsawad; Ai-Lada Intrarakamhang; Voranush Chongsrisawat
Journal:  World J Hepatol       Date:  2022-03-27

2.  Risk factors of acute kidney injury after orthotopic liver transplantation in China.

Authors:  Yin Zongyi; Li Baifeng; Zou Funian; Li Hao; Wang Xin
Journal:  Sci Rep       Date:  2017-01-30       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.